Format

Send to

Choose Destination
ACS Chem Biol. 2017 Mar 17;12(3):825-832. doi: 10.1021/acschembio.6b01048. Epub 2017 Feb 6.

Development of Potent, Selective SRPK1 Inhibitors as Potential Topical Therapeutics for Neovascular Eye Disease.

Author information

1
Exonate Ltd , Unit 23, Cambridge Science Park, Cambridge, United Kingdom.
2
Cancer Biology, Division of Cancer and Stem Cells, School of Medicine, University of Nottingham , Queen's Medical Centre, Nottingham NG2 7UH, United Kingdom.
3
School of Chemistry, UNSW Australia , Sydney, Australia.
4
Structural Genomic Consortium, University of Oxford , Old Road Campus, Oxford OX3 7DQ, United Kingdom.
5
Institute for Pharmaceutical Chemistry and Buchmann Institute for Life Sciences, Johann Wolfgang Goethe-University , D-60438, Frankfurt am Main, Germany.
6
School of Physiology and Pharmacology and Neuroscience, University of Bristol , BS8 1TD, Bristol, United Kingdom.
7
School of Medical Sciences, UNSW Australia , Sydney, Australia.

Abstract

Serine/arginine-protein kinase 1 (SRPK1) regulates alternative splicing of VEGF-A to pro-angiogenic isoforms and SRPK1 inhibition can restore the balance of pro/antiangiogenic isoforms to normal physiological levels. The lack of potency and selectivity of available compounds has limited development of SRPK1 inhibitors, with the control of alternative splicing by splicing factor-specific kinases yet to be translated. We present here compounds that occupy a binding pocket created by the unique helical insert of SRPK1, and trigger a backbone flip in the hinge region, that results in potent (<10 nM) and selective inhibition of SRPK1 kinase activity. Treatment with these inhibitors inhibited SRPK1 activity and phosphorylation of serine/arginine splicing factor 1 (SRSF1), resulting in alternative splicing of VEGF-A from pro-angiogenic to antiangiogenic isoforms. This property resulted in potent inhibition of blood vessel growth in models of choroidal angiogenesis in vivo. This work identifies tool compounds for splice isoform selective targeting of pro-angiogenic VEGF, which may lead to new therapeutic strategies for a diversity of diseases where dysfunctional splicing drives disease development.

PMID:
28135068
DOI:
10.1021/acschembio.6b01048
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for American Chemical Society
Loading ...
Support Center